DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Improved drug delivery across the blood-brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry
Crossing the blood-brain barrier (BBB) remains a major challenge in drug delivery for central nervous system (CNS) diseases. This study presents a covalent functionalization strategy to attach cannabidiol (CBD), the major non-psychotropic phytocannabinoid, to lipid nanocapsules (LNCs) to enhance their BBB permeability in vitro and in vivo. Using click chemistry, two highly monodisperse CBD-functionalized LNC formulations are prepared, LNC1CBD and LNC2CBD, with sizes of 27.0 ± 0.8 nm and 55.0 ± 2.5 nm, and functionalization efficiencies of 30.82 ± 5.93% and 29.59 ± 8.34%, respectively. LNC2CBD exhibits a 55.77% increase in cellular uptake relative to non-functionalized LNCs. In vitro permeability assays demonstrate that LNC1CBD significantly enhances translocation across the healthy BBB at earlier timepoints (4, 8 and 12 h), whereas LNC2CBD exhibits enhanced permeability at later stages (12 and 24 h) compared to their non-functionalized counterparts. This trend is maintained in a diseased BBB model, where CBD functionalization significantly improves permeability at nearly all timepoints for both formulations. Biodistribution studies in healthy mice validate these findings. LNC1CBD significantly increases brain accumulation by 14.87% at 30 min, while LNC2CBD maintains this effect, reaching 17.64% at 30 min, 38.23% at 90 min and 73.53% at 240 min, relative to non-functionalized LNCs. These findings underscore the potential of LNCs covalently functionalized with CBD as a promising platform for CNS-targeted delivery, which can ultimately open new avenues for therapeutic agents that do not usually reach the brain parenchyma at effective concentrations., This work was supported by the Spanish Ministry of Science, Innovation and Universities through the research project PID2019–105531RB-I00/AEI/10.13039/501100011033, titled “Lipid nanocarriers functionalized with cannabidiol for the treatment of brain tumours (NANOGLIO)”. Furthermore, A.P.L acknowledges the Community of Madrid for his contract (Ref. PIPF-2022/SAL-GL-25048) and the Complutense University of Madrid for funding a research stay at i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal under the Erasmus Plus program. L.G.L acknowledges the Complutense University of Madrid and Santander Bank for financial support (CT82/20-CT83/20). This work was supported by MOBILIsE Project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 951723. This work was also supported by FCT—Fundação para a Ciência e a Tecnologia in the framework of the project COMPETE2030-FEDER-00683900. C. M. acknowledges CEEC contract (2023.07049.CEECIND). V. S. acknowledges support from the Spanish Ministry of Science and Innovation (grant PID2021–127847OB-I00), as well as the CIBER-BBN, ELECMI and NANBIOSIS ICTSs., Peer reviewed